TY - JOUR
T1 - Cerebral Edema in Patients With Large Ischemic Core After Thrombectomy
T2 - A Secondary Analysis of SELECT2 Randomized Trial
AU - for the SELECT2 Investigators
AU - Ng, Felix
AU - Yogendrakumar, Vignan
AU - Johns, Hannah
AU - Churilov, Leonid
AU - Hassan, Ameer
AU - Abraham, Michael
AU - Ortega‑Gutierrez, Santiago
AU - Hussain, M. Shazam
AU - Chen, Michael
AU - Sitton, Clark W.
AU - Kasner, Scott E.
AU - Sharma, Gagan
AU - Guha, Prodipta
AU - Pujara, Deep
AU - Mendes Pereira, Vitor
AU - Lansberg, Maarten G.
AU - Wechsler, Lawrence
AU - Nguyen, Thanh N.
AU - Fifi, Johanna T.
AU - Hill, Michael D.
AU - Ribo, Marc
AU - Parsons, Mark W.
AU - Davis, Stephen M.
AU - Grotta, James
AU - Albers, Gregory W.
AU - Campbell, Bruce C.V.
AU - Sarraj, Amrou
N1 - Publisher Copyright:
© 2026 American Heart Association, Inc.
PY - 2026
Y1 - 2026
N2 - BACKGROUND: – Cerebral edema is a life-threatening complication of ischemic stroke that disproportionally affects patients with large established infarction. We assessed whether endovascular thrombectomy (EVT) reduces or exacerbates edema development, and the association between edema with short-term and long-term outcomes in this high-risk population. METHODS: – In this prespecified secondary analysis of the SELECT2 randomized clinical trial (Randomized Controlled Trial to Optimize Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke), which tested the efficacy and safety of EVT versus medical management in adult patients with acute anterior circulation large vessel occlusion presenting with large ischemic core (defined as Alberta Stroke Program Early Computed Tomography Score of 3–5 or core volume ≥50 mL on computed tomography perfusion or diffusion magnetic resonance imaging), we assessed maximum midline shift (MLS) within 7 days of randomization between treatment groups using a probabilistic index model. RESULTS: – After exclusion of 10 patients who underwent hemicraniectomy before follow-up imaging, 342 patients were analyzed. The median MLS on follow-up magnetic resonance imaging or computed tomography was 6.39 mm (interquartile range, 0–12.0) in the EVT and 4.18 mm (interquartile range, 0–9.66) in medical management patients (P=0.021). EVT was independently associated with greater MLS (adjusted odds ratio, 1.63 [95% CI, 1.25–2.12]; P=0.0027) after adjusting for age and core volume. There was no interaction between EVT and core volume at presentation on the association with MLS (P>0.79). MLS was associated with the development of early neurological worsening (adjusted odds ratio, 1.15 [95% CI, 1.07–1.23]; P<0.001), and a lower likelihood of long-term functional improvement assessed on modified Rankin Scale score at 90 days (adjusted odds ratio, 0.96 [95% CI, 0.93–0.98]; P=0.0029). On mediation analysis, cerebral edema reduced the effect of EVT on functional outcome by 10.6%. CONCLUSIONS: – Despite overall clinical benefit, EVT in patients presenting with a large ischemic core was associated with increased cerebral edema, which, in turn, was associated with early neurological worsening and worse functional outcome at 90 days. Early recognition and individualized treatment to prevent secondary injury from cerebral edema in this population are warranted. REGISTRATION: – URL: https://www.clinicaltrials.gov; Unique identifier: NCT03876457.
AB - BACKGROUND: – Cerebral edema is a life-threatening complication of ischemic stroke that disproportionally affects patients with large established infarction. We assessed whether endovascular thrombectomy (EVT) reduces or exacerbates edema development, and the association between edema with short-term and long-term outcomes in this high-risk population. METHODS: – In this prespecified secondary analysis of the SELECT2 randomized clinical trial (Randomized Controlled Trial to Optimize Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke), which tested the efficacy and safety of EVT versus medical management in adult patients with acute anterior circulation large vessel occlusion presenting with large ischemic core (defined as Alberta Stroke Program Early Computed Tomography Score of 3–5 or core volume ≥50 mL on computed tomography perfusion or diffusion magnetic resonance imaging), we assessed maximum midline shift (MLS) within 7 days of randomization between treatment groups using a probabilistic index model. RESULTS: – After exclusion of 10 patients who underwent hemicraniectomy before follow-up imaging, 342 patients were analyzed. The median MLS on follow-up magnetic resonance imaging or computed tomography was 6.39 mm (interquartile range, 0–12.0) in the EVT and 4.18 mm (interquartile range, 0–9.66) in medical management patients (P=0.021). EVT was independently associated with greater MLS (adjusted odds ratio, 1.63 [95% CI, 1.25–2.12]; P=0.0027) after adjusting for age and core volume. There was no interaction between EVT and core volume at presentation on the association with MLS (P>0.79). MLS was associated with the development of early neurological worsening (adjusted odds ratio, 1.15 [95% CI, 1.07–1.23]; P<0.001), and a lower likelihood of long-term functional improvement assessed on modified Rankin Scale score at 90 days (adjusted odds ratio, 0.96 [95% CI, 0.93–0.98]; P=0.0029). On mediation analysis, cerebral edema reduced the effect of EVT on functional outcome by 10.6%. CONCLUSIONS: – Despite overall clinical benefit, EVT in patients presenting with a large ischemic core was associated with increased cerebral edema, which, in turn, was associated with early neurological worsening and worse functional outcome at 90 days. Early recognition and individualized treatment to prevent secondary injury from cerebral edema in this population are warranted. REGISTRATION: – URL: https://www.clinicaltrials.gov; Unique identifier: NCT03876457.
KW - brain edema
KW - ischemic stroke
KW - perfusion
KW - thrombectomy
KW - tomography
UR - https://www.scopus.com/pages/publications/105036849306
U2 - 10.1161/STROKEAHA.125.054015
DO - 10.1161/STROKEAHA.125.054015
M3 - Artículo
C2 - 41906875
AN - SCOPUS:105036849306
SN - 0039-2499
JO - Stroke
JF - Stroke
ER -